Abstract
Background: In the 1990s, the beta interferons and glatiramer acetate were introduced for treating relapsing-remitting multiple sclerosis. These medications have a demonstrated record of efficacy and safety, although they require frequent administration via injection and are only partially effective. The optimization of treatment in patients who do not respond adequately to this first-line therapy is essential for attaining the best long-term outcomes. Switching to the recently approved emergent therapies is a strategy to consider for treatment of patients with a suboptimal response.
Objective: This review summarizes the mechanisms of action, clinical benefits, and safety profiles of current multiple sclerosis disease-modifying therapies, including highly efficacious monoclonal antibodies or convenient oral therapies, and with a special focus on the pegylated interferon beta 1a formulation.
Methods: We reviewed the recent literature and human clinical trials on multiple sclerosis therapies by bibliographic search in PubMed and clinicaltrials.gov.
Results and Conclusion: Although the first-line interferon beta exhibits a favorable benefit-torisk profile, treatment compliance is compromised potentially due to its known adverse events and frequent injectable administration. Less frequent dosing and improved pharmacological properties have been achieved by reaction of interferon beta with chemically activated polyethylene glycol. Provided that none of the available therapies show better effectiveness for all outcomes and their safety in clinical practice is of a fundamental concern, the pegylated form of interferon beta seems to keep its place as a competitive therapeutic option.
Keywords: Pegylated interferon beta, PEG-IFN-β, multiple sclerosis, emergent therapies, treatment strategies, therapy optimization, management of MS patients.
Current Medicinal Chemistry
Title:New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis
Volume: 25 Issue: 27
Author(s): Miguel Angel Ortiz*, Laura Espino-Paisan*, Concepcion Nunez, Roberto Alvarez-Lafuente and Elena Urcelay
Affiliation:
- Red Espanola de Esclerosis Multiple (REEM), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Ministerios de Economia y Competitividad, Madrid,Spain
- Red Espanola de Esclerosis Multiple (REEM), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Ministerios de Economia y Competitividad, Madrid,Spain
Keywords: Pegylated interferon beta, PEG-IFN-β, multiple sclerosis, emergent therapies, treatment strategies, therapy optimization, management of MS patients.
Abstract: Background: In the 1990s, the beta interferons and glatiramer acetate were introduced for treating relapsing-remitting multiple sclerosis. These medications have a demonstrated record of efficacy and safety, although they require frequent administration via injection and are only partially effective. The optimization of treatment in patients who do not respond adequately to this first-line therapy is essential for attaining the best long-term outcomes. Switching to the recently approved emergent therapies is a strategy to consider for treatment of patients with a suboptimal response.
Objective: This review summarizes the mechanisms of action, clinical benefits, and safety profiles of current multiple sclerosis disease-modifying therapies, including highly efficacious monoclonal antibodies or convenient oral therapies, and with a special focus on the pegylated interferon beta 1a formulation.
Methods: We reviewed the recent literature and human clinical trials on multiple sclerosis therapies by bibliographic search in PubMed and clinicaltrials.gov.
Results and Conclusion: Although the first-line interferon beta exhibits a favorable benefit-torisk profile, treatment compliance is compromised potentially due to its known adverse events and frequent injectable administration. Less frequent dosing and improved pharmacological properties have been achieved by reaction of interferon beta with chemically activated polyethylene glycol. Provided that none of the available therapies show better effectiveness for all outcomes and their safety in clinical practice is of a fundamental concern, the pegylated form of interferon beta seems to keep its place as a competitive therapeutic option.
Export Options
About this article
Cite this article as:
Ortiz Angel Miguel*, Espino-Paisan Laura*, Nunez Concepcion, Alvarez-Lafuente Roberto and Urcelay Elena, New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis, Current Medicinal Chemistry 2018; 25 (27) . https://dx.doi.org/10.2174/0929867325666180226105612
DOI https://dx.doi.org/10.2174/0929867325666180226105612 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Establishment of a High Content Image Platform to Measure NF-κB Nuclear Translocation in LPS-induced RAW264.7 Macrophages for Screening Anti-inflammatory Drug Candidates
Current Drug Metabolism The Treatment of Wrist Osteoarthritis, SLAC Wrist Grade 3-4
Current Rheumatology Reviews The Role of Eosinophils in Non-Parasitic Infections
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitochondrial-Targeted Antioxidants and Oxidative Stress: A Proteomic Prospective Study
Current Pharmaceutical Design Biotransformation of Endocrine Disrupting Compounds by Selected Phase I and Phase II Enzymes – Formation of Estrogenic and Chemically Reactive Metabolites by Cytochromes P450 and Sulfotransferases
Current Medicinal Chemistry Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Identifying and Validating Oncology Therapeutic Targets in the Post- Genomics Era
Current Genomics SS31, a Small Molecule Antioxidant Peptide, Attenuates β-Amyloid Elevation, Mitochondrial/Synaptic Deterioration and Cognitive Deficit in SAMP8 Mice
Current Alzheimer Research Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Nigella Sativa Improve Redox Homeostasis in Heart and Aorta of Diabetic Rat
Current Nutrition & Food Science Familial Mediterranean Fever
Current Rheumatology Reviews Bicyclol: A Novel Drug for Treating Chronic Viral Hepatitis B and C
Medicinal Chemistry Therapeutic Potential and Strategies Against Leukocyte-Platelet Interaction in Atherosclerosis
Current Vascular Pharmacology Novel Drugs for Inflammatory Lung Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Mouse In Cancer Research Past, Present, Future
Current Genomics A Novel Technology for Hematopoietic Stem Cell Expansion Using Combination of Nanofiber and Growth Factors
Recent Patents on Nanotechnology Current Understanding of the Molecular Mechanism between Hemodynamic- Induced Intracranial Aneurysm and Inflammation
Current Protein & Peptide Science